PT-141

PT-141

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone (α-MSH). It was developed from melanotan II and differs from it at the C-terminus, where it carries a free carboxylic acid instead of an amide. A lactam bridge between aspartic acid and lysine side chains closes the ring, giving a compact, protease-resistant scaffold that has made it a reference ligand for melanocortin receptor pharmacology.

Product Specifications

• Product: PT-141
• Amount: See available options above
• Form: Lyophilized powder
• Purity: Third-party tested by an ISO 17025 U.S. laboratory. See the batch Certificate of Analysis (COA) on this page.
• Storage: Keep sealed and refrigerated at 2–8°C (36–46°F), protected from light.
• Ships from: United States, 2-day UPS

Chemical Profile

• Compound class: Synthetic cyclic heptapeptide, α-MSH analog (melanocortin receptor agonist)
• Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH (lactam bridge between Asp and Lys side chains)
• Molecular formula: C₅₀H₆₈N₁₄O₁₀
• Molecular weight: 1025.2 g/mol
• CAS number: 189691-06-3

What researchers study

The melanocortin system consists of five G protein-coupled receptors, MC1R through MC5R, that respond to peptides cleaved from pro-opiomelanocortin. PT-141 contains the His-D-Phe-Arg-Trp core that is shared by melanocortin agonists and binds several receptor subtypes, with most research attention on MC3R and MC4R, which are expressed in the hypothalamus and other brain regions. Receptor activation signals mainly through G_s and cAMP.

Laboratories use PT-141 to study:

• Receptor pharmacology: binding and cAMP assays across melanocortin receptor subtypes, and structure-activity comparisons with melanotan II and α-MSH.
• Central melanocortin pathways: how MC4R signaling in hypothalamic circuits, including the paraventricular nucleus, connects to downstream neurotransmitter systems.
• Rodent behavioral neuroscience: published rat paradigms that separate appetitive from consummatory behaviors, used to map where in the brain melanocortin signaling acts.
• Cardiovascular pharmacology: blood pressure and heart rate effects of melanocortin agonism, a known feature of this receptor family.

Regulatory status

Bremelanotide is the active ingredient of Vyleesi, a prescription drug product approved by the FDA in June 2019 for a specific indication: acquired, generalized hypoactive sexual desire disorder in premenopausal women. The material sold here is a research reagent, not an approved drug product, and is not for human use.

Quality & Documentation

Every batch of PT-141 is made in small runs for Rogue Compounds and tested by an independent U.S. laboratory for identity (mass spectrometry) and purity (HPLC). Each vial is labeled with its batch number and a QR code that opens the testing lab’s own report for that batch. The same batch Certificate of Analysis is posted on this page and in our COA Library, so you can check one against the other.

Research overview

For a longer look at PT-141 (Bremelanotide), covering where it came from, what cell and animal studies have measured, and what the evidence does not show, read our PT-141 (Bremelanotide) research overview. It is written as background reading, and every study it cites is linked to PubMed.

Selected literature

• Molinoff PB, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. PMID 12851303
• Pfaus JG, et al. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci USA. 2004;101(27):10201-10204. PMID 15226502
• Pfaus J, Giuliano F, Gelez H. Bremelanotide: an overview of preclinical CNS effects on female sexual function. J Sex Med. 2007;4 Suppl 4. PMID 17958619
• Diamond LE, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16(1):51-59. PMID 14963471

Research Use Only

This product is sold strictly as a research chemical for in-vitro laboratory and analytical use by qualified professionals. It is not a drug, dietary supplement, food, or cosmetic, and it is not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Rogue Compounds does not provide dosing, preparation, or usage instructions. The literature on this page is listed for scientific background only and does not describe this product or any use of it.